临床试验
心理干预
透视图(图形)
医学
知情同意
替代医学
临床平衡
护理部
内科学
计算机科学
病理
人工智能
作者
Patrick M. Kane,Merlin Bittlinger,Jonathan Kimmelman
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2021-10-12
卷期号:27 (10): 1679-1686
被引量:7
标识
DOI:10.1038/s41591-021-01519-y
摘要
‘Individualized therapy’ trials (sometimes called n-of-1 trials) use patients as their own controls to evaluate treatments. Here we divide such trials into three categories: multi-crossover trials aimed at individual patient management, multi-crossover trial series and pre–post trials. These trials all customize interventions for patients; however, the latter two categories also aim to inform medical practice and thus embody tensions between the goals of care and research that are typical of other types of clinical trials. In this Perspective, we discuss four domains where such tensions play out—clinical equipoise, informed consent, reporting and funding, and we provide recommendations for addressing each. In this Perspective, the authors discuss the ethical challenges of individualized therapy (also called n-of-1) trials and argue that, although customized for the patient, these constitute ‘research’ nonetheless.
科研通智能强力驱动
Strongly Powered by AbleSci AI